Changchun High-Tech Industry's (SHE:000661) unit, Changchun Jinsai Pharmaceutical, received the approval of China's National Medical Products Administration for the clinical trial application of GS3-007a dry suspension, according to a Shenzhen bourse filing on Saturday.
The shares of the Chinese biopharmaceutical product manufacturer fell by less than 2% during Monday morning's trade.
The drug is being developed as a treatment for patients with pediatric growth hormone deficiency.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments